Cargando…
Tumor cells with KRAS or BRAF mutations or ERK5/MAPK7 amplification are not addicted to ERK5 activity for cell proliferation
ERK5, encoded by MAPK7, has been proposed to play a role in cell proliferation, thus attracting interest as a cancer therapeutic target. While oncogenic RAS or BRAF cause sustained activation of the MEK1/2-ERK1/2 pathway, ERK5 is directly activated by MEK5. It has been proposed that RAS and RAF prot...
Autores principales: | Lochhead, Pamela A., Clark, Jonathan, Wang, Lan-Zhen, Gilmour, Lesley, Squires, Matthew, Gilley, Rebecca, Foxton, Caroline, Newell, David R., Wedge, Stephen R., Cook, Simon J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5056618/ https://www.ncbi.nlm.nih.gov/pubmed/26959608 http://dx.doi.org/10.1080/15384101.2015.1120915 |
Ejemplares similares
-
Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: Implications for the treatment of human liver cancer
por: Wang, Chunmei, et al.
Publicado: (2013) -
ERK5 Signalling and Resistance to ERK1/2 Pathway Therapeutics: The Path Less Travelled?
por: Cook, Simon J., et al.
Publicado: (2022) -
Small molecule ERK5 kinase inhibitors paradoxically activate ERK5 signalling: be careful what you wish for…
por: Cook, Simon J., et al.
Publicado: (2020) -
“Dark matter” worlds of unstable RNA and protein
por: Baboo, Sabyasachi, et al.
Publicado: (2014) -
Extrusion without a motor: a new take on the loop extrusion model of genome organization
por: Brackley, C. A., et al.
Publicado: (2018)